APLT Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

$11.48
As of 11/30/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/08/2019
Outstanding shares:  26,215,514
Average volume:  83,565
Market cap:   $285,224,792
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03828A101
ISIN:        US03828A1016
Sedol:      BJL38Z1
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.26
PS ratio:   0.00
Return on equity:   -117.78%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy